Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide

J. Van Hoogenhuijze, J. Lankelma, J. Stam, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.

Original languageEnglish (US)
Pages (from-to)807-811
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number6
DOIs
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide'. Together they form a unique fingerprint.

  • Cite this